The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
List view / Grid view
Filter the results
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
Sales of Merck’s drug Keytruda have grown beyond those of Bristol-Myers Squibb’s Opdivo, to become the global leading PD-1 inhibitor.
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Adjuvant nivolumab has been found to be more superior than ipilimumab in the standard of care in patients with surgically resected stage III/IV melanoma...
Alternative immunotherapy drug nivolumab is more effective than current standard of care in treating advanced melanoma after surgical removal of disease.
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company’s immuno-oncology (I-O) portfolio.